Phase I Clinical-Pharmacology Program

Karmanos' Phase I Clinical-Pharmacology Multidisciplinary Team directs the only National Cancer Institute-funded Phase I program in Michigan. This unique program conducts clinical research studies with new investigational cancer drugs. Phase I trials are the first stage of clinical trials in the careful process of developing new cancer treatments. A typical Phase I clinical trial evaluates how a new drug should be given, either orally or injected into the blood, how often and what dosage is safe. A Phase I trial is often the first time a drug has been given to human, or the first time a new drug has been given to a human in combination with another standard cancer treatment. The team meets with and treats patients at the state-of-the-art Eisenberg Center for Translational Therapeutics, located at Karmanos Cancer Center in Detroit.

Karmanos' Phase I Clinical-Pharmacology Specialists

The Phase I Team is comprised of members from an array of clinical sub-specialties at Karmanos. They collaborate to create the best treatment plans for each patient. The Phase I Team works across all Karmanos multidisciplinary teams to ensure that eligible patients are aware of their clinical trial options

Evaluation & Diagnosis

Each patient receives personal attention from the Phase I Team. All patients considered for a Phase I clinical trial must go through an initial screening consultation to determine if they are eligible for a research study and if a clinical trial is their best treatment option.

During your initial visit, a Phase I Team physician will evaluate you and review your medical records. The physician will discuss treatment recommendations with you, your family and your referring physician. After all parties agree upon the treatment recommendation, you will need to sign consent forms to participate in the clinical trial. Patient safety and care are our top priorities. Phase I Team physicians, along with Phase I nurse practitioners and physician assistants will monitor you very carefully for any changes in your condition and will maintain close contact with your referring physician. You may opt-out of a clinical trial at any time

Due to the complicated nature of research studies, treatment may begin several weeks after your initial appointment. All clinical trials are conducted under specific Wayne State University Institutional Review Board and Karmanos Cancer Institute scientific peer-review approval.

Innovative, Individualized Care

Here’s what patients can expect from our Phase I Clinical-Pharmacology Multidisciplinary Team:

  • A passionate, caring, expert team, giving you the best chance of success.
  • A collaborative approach that considers all available treatment options, including clinical trials, for your specific type of breast cancer.
  • A carefully constructed treatment plan designed to achieve the best possible outcome.
  • Respectful, compassionate care that is responsive to your emotional needs and lifestyle.
  • Proactive, timely communication with you and your loved ones, and your personal physician.

Appointment Information

To schedule an appointment with the Karmanos Phase I Clinical-Pharmacology Team, please fill out this appointment request form.

Meet Our Multidisciplinary Team
Phase I Clinical-Pharmacology Program

The Latest From Karmanos Cancer Institute

News

Carl Pfadt: Fighting sarcoma, the forgotten cancer

Often called the “forgotten cancer,” sarcoma refers to more than 70 subtypes of cancer that affect the body’s connective tissue. "Sarcomas are rar...

Read More

Karmanos researchers look to cancer studies to understand racial disparities in health care

Cancer and COVID-19 vary vastly in their classification, treatment and symptoms but the two have something in common: they are disproportionately ...

Read More

Karmanos launches COVID-19, Cancer & Community survey to assess the impact of COVID-19 response on the health habits of Michiganders

Karmanos Cancer Institute has launched a survey to ask community members about their experiences with health care during the COVID-19 pandemic. Qu...

Read More